Advanced Prostate Cancer VL

Novel STEAP1 Targeted BiTE Therapy Demonstrates Early Efficacy in Phase 1 Trial - William Kevin Kelly

Details
Kevin Kelly discusses a groundbreaking approach to prostate cancer treatment with Alicia Morgans. He presents Xaluritamig (AMG 509) a novel bi-specific antibody targeting the STEAP1 protein, prevalent in prostate cancer cells. This innovative therapy, a form of biTE therapy, is designed to attract T-cells for targeted cytotoxicity. In a phase one trial involving advanced prostate cancer patients w...

Shifting Clinical Trial Design Towards Improving Patient Enrollment - Michael Morris

Details
Alicia Morgans engages with Michael Morris to discuss the transformation of clinical trial design to improve patient access and applicability of results. Dr. Morris highlights the complexity of current clinical trials, which often involve extensive documentation and stringent eligibility criteria, limiting participation to a narrow patient population and placing a heavy burden on both participants...

AMG 509's Potential in Prostate Cancer Therapy - Michael Morris

Details
Michael Morris highlights notable prostate cancer trials, focusing on AMG 509, a bispecific antibody targeting STEAP1 and CD3. This promising early-phase study, still determining optimal dosages, shows potential in treating prostate cancer, a field historically resistant to immune therapy. Dr. Morris emphasizes AMG 509's ability to reduce bony and visceral diseases, including liver disease, with m...

Genetic Testing Reveals Treatment Opportunity and Disparity in Advanced Prostate Cancer - Colin Pritchard

Details
Zach Klaassen engages with Colin Pritchard in a detailed discussion about genomic testing in prostate cancer. They emphasize the importance of genomic testing, particularly in advanced prostate cancer, for treatment decisions and family counseling. Dr. Pritchard highlights the clinical utility of both germline and somatic testing, especially in metastatic cases, and discusses the timing and types...

Medicare Data Compares Enzalutamide and Abiraterone Outcomes in mCRPC Patients - Dan George

Details
Zach Klaassen speaks with Dan George about a key study comparing Enzalutamide (Enza) and Abiraterone (Abi) in pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC). This study addresses a significant gap in head-to-head clinical trials for these drugs. Dr. George discusses various data sources, including the French National Database, Flatiron, and VA data, all indicating a survi...

Sequencing Therapies in Advanced Prostate Cancer Requires Balancing Many Factors - Rana McKay

Details
Alicia Morgans and Rana McKay delve into the complexities of treatment sequencing for metastatic castration-resistant prostate cancer. They highlight the expansive range of available therapies, including hormonal, targeted, immunotherapies, chemotherapy, and radioligand therapies. The focus is on the importance of patient involvement in decision-making, considering individual preferences, lifestyl...

Attacking Androgen Receptor From Two Sides: The Potential of a Novel Drug Duo in Prostate Cancer - Christos Kyriakopoulos

Details
Alicia Morgans interviews Christos Kyriakopoulos about a study presented at ESMO on EPI-7386, also known as masofaniten. Dr. Kyriakopoulos elaborates on this phase one-two study, which explores the combination of EPI-7386 with enzalutamide in patients with metastatic castration-resistant prostate cancer. EPI-7386 is novel in targeting the androgen receptor's N-terminal domain, differing from other...

The PSMAfore Trial and its Role in Shaping Future Prostate Cancer Treatments - Oliver Sartor

Details
In a discussion with Alicia Morgans, Oliver Sartor delves into the innovative PSMAfore trial, focusing on treating metastatic CRPC in taxane-naive patients using PSMA PET-positive lesions. This trial, evolving from the VISION trial, aims to expand treatment eligibility by initiating therapy before chemotherapy, addressing the fact that nearly half of metastatic prostate cancer patients never recei...

Clinical Implications and Patient Care: The SNMMI Consensus on Lutetium PSMA 617 Therapy for Advanced Prostate Cancer - Heather Jacene & Oliver Sartor

Details
Alicia Morgans facilitates a discussion with Heather Jacene and Oliver Sartor regarding the SNMMI consensus statement on the use of Lutetium PSMA-617 radionuclide therapy for advanced prostate cancer. This multidisciplinary consensus, crafted by nuclear medicine physicians and medical oncologists, dives deep into the complexities of the metastatic CRPC space. While Lutetium PSMA-617 emerges as a p...

Influencing Best Practices for Genomic and Germline Testing in Urology - Abhishek Srivastava

Details
Zach Klaassen speaks with Abhishek Srivastava about the significance of germline and genomic testing in advanced prostate cancer. Dr. Srivastava elaborates on his recent publication, which aims to improve the penetration of such testing in urology, particularly in community practices. He emphasizes the importance of cascade testing for identifying actionable mutations and influencing treatment opt...